Compass Group PLC Sponsored ADR (CMPGY)
Compass CEO: Mamdani win has paused homebuying more than any event in my 13 years of NYC real estate
Robert Reffkin, Compass co-founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the impact of New York City mayoral candidate Zohran Mamdani's primary win on real estate, solutions to the city's affordability crisis, and more.
Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billion by 2035.
Real estate company Compass sues Zillow over consumers 'right to choose'
Real estate brokerage Compass sues Zillow for allegedly abusing monopoly power, claiming platform restrictions on listings violate antitrust laws.
Compass is Suing Zillow Over New Listing Rules. Why Buyers and Sellers Should Pay Attention.
At the heart of the rift is a disagreement over industry norms that could change how buyers shop and how sellers list homes.
Real Estate Broker Compass Accuses Zillow of ‘Anticompetitive' Behavior
Real estate brokerage Compass has reportedly sued Zillow for its ban on private home listings. [contact-form-7] The suit, filed Monday (June 23) in federal court in Manhattan, accuses Zillow of employing “anticompetitive tactics to protect its monopoly and revenues in violation of the antitrust laws,” the Associated Press (AP) reported.
atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) remains a ‘Buy' for analysts at Jefferies, who continue to see significant upside ahead for the company following the release of new data from Compass Pathways (NASDAQ:CMPS)' late-stage trial of its synthetic psilocybin COMP360 in treatment-resistant depression (TRD). Compass Pathways on Monday reported that its COMP360 therapy reached its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo.
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the trial meeting its primary endpoint. A single 25 mg dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo, with a mean difference of 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6.
Compass Pathways' depression drug succeeds late-stage trial
Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.
Compass: Harnessing Your Technological Potential Before It's Late
Compass is gaining market share by empowering agents with advanced technology, leading to record agent growth even in a tough real estate market. Despite revenue reliance on transaction fees, Compass demonstrates stable revenues, growing free cash flow, and a rapidly improving balance sheet. The company is nearing profitability, with net losses shrinking and adjusted EBITDA turning positive, reflecting operational efficiency and effective cost control.
Compass Diversified Takes Decisive Steps Amid Lugano Probe, Stock Dips
CODI suspends payouts, cuts fees and restricts Lugano investments amid probe. Its shares plummet 10.2% after trading hours.
Compass Group eyes margin boost as vending machines quietly power ahead
Compass Group PLC (LSE:CPG) has long been seen as a reliable operator, benefiting from steady contract wins and its scale in procurement. But according to UBS, there is more going on under the bonnet, and it could help push profit margins higher than many expect.
Compass: Building A Real Estate Goliath While The Industry Is Weak
Compass is outperforming the shrinking real estate industry, growing market share both organically and through acquisitions, despite challenging macro conditions. Innovative product offerings and international expansion, including the Christie's acquisition, are driving growth and attracting agents and sellers to the Compass platform. Profitability is improving meaningfully, with rising attach rates for title, and escrow services and disciplined operating expense growth supporting adjusted EBITDA gains.
